Goldstein Dov A Md

Insider Reports History

Signature
/s/ David Snyder, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Goldstein Dov A Md:

Stock Role Class Num Shares Value Price $ Report Date Ownership
BioAge Labs, Inc. Chief Financial Officer Common Stock 22.4K $403K $18.00 Sep 25, 2024 Direct
Coya Therapeutics, Inc. Director Common Stock, par value $0.0001 per share 27.6K $30K $1.09 Aug 18, 2025 Direct
BioAge Labs, Inc. Chief Financial Officer Stock Option (Right to Buy) 170K Feb 18, 2025 Direct
NeuBase Therapeutics, Inc. Director Stock option (right to buy) 37.6K Sep 9, 2022 Direct
Gain Therapeutics, Inc. Director Stock Option (right to buy) 15K Jun 24, 2025 Direct
Coya Therapeutics, Inc. Director Stock Option (right to buy) 0 Aug 18, 2025 Direct

Insider Reports Filed by Goldstein Dov A Md

Symbol Company Period Transactions Value $ Form Type Date Filed Role
COYA Coya Therapeutics, Inc. Aug 18, 2025 2 $19.1K 4 Aug 19, 2025 Director
GANX Gain Therapeutics, Inc. Jun 24, 2025 1 $0 4 Jun 25, 2025 Director
COYA Coya Therapeutics, Inc. Feb 25, 2025 1 $0 4 Feb 25, 2025 Director
BIOA BioAge Labs, Inc. Feb 18, 2025 1 $0 4 Feb 20, 2025 Chief Financial Officer
COYA Coya Therapeutics, Inc. Jan 1, 2025 1 $0 4 Jan 3, 2025 Director
BIOA BioAge Labs, Inc. Sep 25, 2024 0 $0 3 Sep 25, 2024 Chief Financial Officer
GANX Gain Therapeutics, Inc. Jun 24, 2024 1 $0 4 Jun 26, 2024 Director
COYA Coya Therapeutics, Inc. Jan 1, 2024 1 $0 4 Jan 19, 2024 Director
GANX Gain Therapeutics, Inc. Jun 23, 2023 1 $0 4 Jun 26, 2023 Director
COYA Coya Therapeutics, Inc. Jan 3, 2023 2 $0 4 Jan 4, 2023 Director
COYA Coya Therapeutics, Inc. Dec 28, 2022 0 $0 3 Dec 28, 2022 Director
GANX Gain Therapeutics, Inc. Sep 20, 2022 1 $0 4 Sep 22, 2022 Director
NBSE NeuBase Therapeutics, Inc. Sep 9, 2022 1 $0 4 Sep 12, 2022 Director
NBSE NeuBase Therapeutics, Inc. Aug 19, 2021 1 $0 4 Sep 17, 2021 Director
NBSE NeuBase Therapeutics, Inc. Jun 18, 2021 1 $38K 4 Jun 21, 2021 Director